Brief: AnaptysBio Q3 net income USD -37.308 million
02/11/2023 20:29
Nov 2 (Reuters) - AnaptysBio Q3 collaboration revenue USD 3.318 million. * Q3 operating expenses USD 41.05 million * Q3 income from operations USD -37.732 million * Q3 net income USD -37.308 million
Recent news on AnaptysBio
See all newsFirst Tracks Biotherapeutics up after $200 mln equity raise
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Brief: Anaptys Announces Second Quarter And Transitional Fiscal Year 2026 Financial Results And Provides Business Update
AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties